Compare Humpuss Maritim Internasional Tbk. (HUMI) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humpuss Maritim Internasional Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Humpuss Maritim Internasional Tbk. trades at Rp137 (market cap 2.47T, 40.18M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Humpuss Maritim Internasional Tbk. is far larger — about 23.7× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| HUMI | SCPI | |
|---|---|---|
Market Cap | 2.47T | 104.4B |
Volume | 40.18M | — |
Lot | 401.82K | — |
Turnover | 5.4B | — |
Average Price | 134.5 | — |
Value | 5.4B | — |
Indicative Equilibrium Price | 137 | — |
Indicative Equilibrium Volume | 13.29K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humpuss Maritim Internasional Tbk.
PT Humpuss Maritim Internasional Tbk. (the Company) is a limited liability company incorporated under the laws of the Republic of Indonesia by virtue of Notarial Deed No. 21 dated September 29, 2016 of Martina, S.H., Notary in Jakarta. The Company change its name from PT MISI Hutama Internasional to PT Humpuss Maritim Internasional. The Company has started its commercial operation since December 2016. Parent entity ofthe Company is PT Humpuss Transportasi Kimia and ultimate parent of the Company is PT Humpuss Intermoda Transportasi Tbk. The Company’s controlling party is H. Hutomo Mandala Putra, SH.
Read more on HUMI →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
